SCHEMBL692852

SCHEMBL692852

CCOC(=O)c1nnc(-c2cccc(NS(=O)(=O)C(F)(F)F)c2)o1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 6/20 0.43
ALDH1A1 P00352 5/20 0.43
MAPT P10636 5/20 0.43
KDM4E B2RXH2 4/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
USP2 O75604 2/20 0.42
HPGD P15428 4/20 0.42
NPSR1 Q6W5P4 4/20 0.42
HSD17B10 Q99714 2/20 0.42
TP53 P04637 2/20 0.42
TSHR P16473 5/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPK1 P28482 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL692879 0.87 CA1 (0.61) CA1CA2SMN1; SMN2ALDH1A1MAPT
SCHEMBL9611047 0.85 SMN1; SMN2 (0.48) CA2CYP3A4CYP2D6CYP2C19SMN1; SMN2
SCHEMBL9611048 0.80 TP53 (0.49) SMN1; SMN2MAPTKDM4ENPC1RAB9A
SCHEMBL24073573 0.79 MAPT (0.56) CA1CA2SMN1; SMN2ALDH1A1MAPT
SCHEMBL30975808 0.78 CA1 (0.52) CA1CA2SMN1; SMN2ALDH1A1MAPT
SCHEMBL25257893 0.78 CA1 (0.52) CA1CA2SMN1; SMN2ALDH1A1MAPT
SCHEMBL20266995 0.78 CA1 (0.56) CA1CA2CYP3A4CYP2D6CYP2C19
SCHEMBL25837758 0.78 CA1 (0.58) CA1CA2CYP3A4CYP2D6CYP2C19
SCHEMBL691809 0.77 SMN1; SMN2 (0.59) CA1CA2CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL691309 0.76 EPHX2 (0.48) SMN1; SMN2MAPTKDM4EUSP2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560643-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES Institute for OneWorld Health (US) 2013-02-27 EP disclosed
US-20120136003-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-31 US disclosed
EP-2421528-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES Institute for OneWorld Health (US) 2012-02-29 EP disclosed
US-20110288103-A1 COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed
WO-2011133596-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-10-27 WO disclosed
WO-2010123933-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136003-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES CFTR, PKD1, PKD2 CA1 3753/4885CA2 1288/4885CYP3A4 2131/4885
US-20110288103-A1 COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES ORAI1, ATP2A3, ANO1 CA1 237/4885CA2 7/4885CYP3A4 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.